Overexpression of TERF2IP has been observed in breast, gastric, non-small cell lung, condylomatous lymphoma, multiple melanoma, colorectal, and renal cell carcinomas (Panero et al., 2014; Panero et al., 2016; Pal et al., 2017; Xiao et al., 2017; Anu et al., 2020; Bhari et al., 2021). Here, TERF2IP is linked to hereditary clear cell renal cell carcinoma.